Israeli clinical stage biotechnology company at Holon near Tel Aviv, founded in 1993 and listed in New York and Tel Aviv, which uses computational discovery to find new drug targets. Predicts and validates novel immune checkpoint targets from genomic and proteomic data, develops antibody therapies against them for cancer immunotherapy including programmes partnered with larger pharmaceutical companies, and runs its own computational, laboratory and translational research.
No hay comentarios disponibles.
Deja tu valoración & comentario